Development of Covalently Closed c-myb Antisense Oligonucleotides for Growth Inhibition of Leukemic Cells.
- Author:
Ik Mae MOON
1
;
Jong Gu PARK
Author Information
1. Institute for Medical Science, Dongsan Medical Center, Keimyeung University, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
Leukemic cells;
Antisense oligos;
c-myb
- MeSH:
Cell Line;
Computer Simulation;
Genes, myb;
Liposomes;
Oligonucleotides, Antisense*;
RNA, Messenger
- From:Journal of the Korean Cancer Association
1999;31(2):348-359
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Aberrant expression of the c-myb gene is often detected in transformed leukemic cells. Inhibition of c-myb expression by antisense oligos could be an effective way to abort rapid growth of leukemic cells. Developing stable antisense oligos combined with enhanced delivery into cells would be of great use in developing an effective anti-cancer molecular agent. MATERIALS AND METHODS: Selection of target sites was carried out by employing computer simulation of mRNA secondary structures. Multiple antisense oligo sequences were adjoined and AS-oligos were then covalently closed to evade exonuclease activities. C-myb antisense oligos with a novel structure were complexed with cationic liposomes and used to treat HL-60 leukemic cells. RESULTS: We developed covalently closed antisense oligos which harbor four adjoined antisense sequences. The c-myb antisense oligos were found to be exceptionally stable and effective in specifically ablating c-myb mRNA. The antisense oligos were able to inhibit growth of leukemic cell line (HL-60) by about 80%. Antisense effect was more pronounced when the cells were treated twice with the antisense oligos at lower concentrations. CONCLUSION: The novel covalently closed antisense oligo (CMAS-oligos) was found to be effective and exceptionally stable, Growth of HL-60 was significantly inhibited, showing a rational way to develop an effective molecular anti-cancer agent.
